S&P 500   5,123.41
DOW   37,983.24
QQQ   438.27
Closing prices for crude oil, gold and other commodities
How major US stock indexes fared Friday, 4/12/2024
5 Trends You Need to Know This Quarter
MarketBeat Week in Review – 4/8 - 4/12
Faced with possibly paying for news, Google removes links to California news sites for some users
The US and UK restrict the trade of Russian-origin metals
US Steel shareholders approve takeover by Japan's Nippon Steel opposed by Biden administration
S&P 500   5,123.41
DOW   37,983.24
QQQ   438.27
Closing prices for crude oil, gold and other commodities
How major US stock indexes fared Friday, 4/12/2024
5 Trends You Need to Know This Quarter
MarketBeat Week in Review – 4/8 - 4/12
Faced with possibly paying for news, Google removes links to California news sites for some users
The US and UK restrict the trade of Russian-origin metals
US Steel shareholders approve takeover by Japan's Nippon Steel opposed by Biden administration
S&P 500   5,123.41
DOW   37,983.24
QQQ   438.27
Closing prices for crude oil, gold and other commodities
How major US stock indexes fared Friday, 4/12/2024
5 Trends You Need to Know This Quarter
MarketBeat Week in Review – 4/8 - 4/12
Faced with possibly paying for news, Google removes links to California news sites for some users
The US and UK restrict the trade of Russian-origin metals
US Steel shareholders approve takeover by Japan's Nippon Steel opposed by Biden administration
S&P 500   5,123.41
DOW   37,983.24
QQQ   438.27
Closing prices for crude oil, gold and other commodities
How major US stock indexes fared Friday, 4/12/2024
5 Trends You Need to Know This Quarter
MarketBeat Week in Review – 4/8 - 4/12
Faced with possibly paying for news, Google removes links to California news sites for some users
The US and UK restrict the trade of Russian-origin metals
US Steel shareholders approve takeover by Japan's Nippon Steel opposed by Biden administration
NASDAQ:MLTX

MoonLake Immunotherapeutics (MLTX) Stock Price, News & Analysis

$43.91
-1.74 (-3.81%)
(As of 04/12/2024 ET)
Today's Range
$43.35
$45.98
50-Day Range
$43.78
$63.86
52-Week Range
$17.82
$64.98
Volume
438,772 shs
Average Volume
472,479 shs
Market Capitalization
$2.81 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$74.46

MoonLake Immunotherapeutics MarketRank™ Stock Analysis

Analyst Rating
Moderate Buy
2.75 Rating Score
Upside/​Downside
69.6% Upside
$74.46 Price Target
Short Interest
Bearish
16.21% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.34mentions of MoonLake Immunotherapeutics in the last 14 days
Based on 11 Articles This Week
Insider Trading
Selling Shares
$9.49 M Sold Last Quarter
Proj. Earnings Growth
Decreasing
From ($1.11) to ($1.56) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

2.07 out of 5 stars

Medical Sector

590th out of 923 stocks

Pharmaceutical Preparations Industry

275th out of 430 stocks

MLTX stock logo

About MoonLake Immunotherapeutics Stock (NASDAQ:MLTX)

MoonLake Immunotherapeutics, a clinical-stage biopharmaceutical company, engages in developing therapies. It develops Sonelokimab, a novel investigational Nanobody for the treatment of inflammation diseases; and hidradenitis suppurativa, psoriatic arthritis, axial spondyloarthritis, and psoriasis. MoonLake Immunotherapeutics was incorporated in 2020 and is headquartered in Zug, Switzerland.

MLTX Stock Price History

MLTX Stock News Headlines

This tech is sneaking up on Americans’ portfolios
Most Americans have zero idea how advanced A.I. has gotten. To them, it’s still a simple little chatbot that works like a really good version of Google. What they don’t realize is that it is becoming the go-to competitive advantage for people who are serious about their financial well-being. Whether it’s improving productivity at work, replacing employees in their business… or outperforming in the markets. A.I. grants the competitive advantage necessary to get ahead in this economy. It’s become the digital edge that can deliver solid returns… consistently.
This tech is sneaking up on Americans’ portfolios
Most Americans have zero idea how advanced A.I. has gotten. To them, it’s still a simple little chatbot that works like a really good version of Google. What they don’t realize is that it is becoming the go-to competitive advantage for people who are serious about their financial well-being. Whether it’s improving productivity at work, replacing employees in their business… or outperforming in the markets. A.I. grants the competitive advantage necessary to get ahead in this economy. It’s become the digital edge that can deliver solid returns… consistently.
MLTX Aug 2024 80.000 call
MLTX May 2024 60.000 call
MLTX Apr 2024 40.000 put
MoonLake Stock (NASDAQ:MLTX), Short Interest Report
See More Headlines
Receive MLTX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for MoonLake Immunotherapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
2/29/2024
Today
4/13/2024
Next Earnings (Estimated)
5/10/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:MLTX
Fax
N/A
Employees
50
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$74.46
High Stock Price Target
$100.00
Low Stock Price Target
$56.00
Potential Upside/Downside
+69.6%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.75
Research Coverage
12 Analysts

Profitability

Net Income
$-36,010,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$8.15 per share

Miscellaneous

Free Float
54,131,000
Market Cap
$2.81 billion
Optionable
Optionable
Beta
1.20
10 Best Stocks to Own in 2024 Cover

Click the link below and we'll send you MarketBeat's list of the 10 best stocks to own in 2024 and why they should be in your portfolio.

Get This Free Report

MLTX Stock Analysis - Frequently Asked Questions

Should I buy or sell MoonLake Immunotherapeutics stock right now?

12 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for MoonLake Immunotherapeutics in the last twelve months. There are currently 3 hold ratings and 9 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" MLTX shares.
View MLTX analyst ratings
or view top-rated stocks.

What is MoonLake Immunotherapeutics' stock price target for 2024?

12 equities research analysts have issued twelve-month price targets for MoonLake Immunotherapeutics' shares. Their MLTX share price targets range from $56.00 to $100.00. On average, they predict the company's share price to reach $74.46 in the next year. This suggests a possible upside of 69.6% from the stock's current price.
View analysts price targets for MLTX
or view top-rated stocks among Wall Street analysts.

How have MLTX shares performed in 2024?

MoonLake Immunotherapeutics' stock was trading at $60.39 at the beginning of 2024. Since then, MLTX stock has decreased by 27.3% and is now trading at $43.91.
View the best growth stocks for 2024 here
.

When is MoonLake Immunotherapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Friday, May 10th 2024.
View our MLTX earnings forecast
.

How were MoonLake Immunotherapeutics' earnings last quarter?

MoonLake Immunotherapeutics (NASDAQ:MLTX) released its earnings results on Thursday, February, 29th. The company reported ($0.12) earnings per share for the quarter, beating analysts' consensus estimates of ($0.23) by $0.11.

How do I buy shares of MoonLake Immunotherapeutics?

Shares of MLTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:MLTX) was last updated on 4/13/2024 by MarketBeat.com Staff

From Our Partners